Literature DB >> 7525302

Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815.

B Van den Eynde1, H Mazarguil, B Lethé, F Laval, J E Gairin.   

Abstract

Mouse mastocytoma P815 expresses tumor antigens P815A and P815B encoded by a single gene called P1A and carried by a single peptide named P1A 35-43 (NH2-Leu-Pro-Tyr-Leu-Gly-Trp-Leu-Val-Phe-COOH). P1A 35-43 is presented to anti-P815A and anti-P815B cytotoxic T lymphocytes (CTL) by major histocompatibility complex (MHC) H-2Ld molecules. In order to determine the individual role played by each amino acid residue of P1A 35-43 in binding to H-2Ld and in recognition by anti-A and anti-B T cell receptors (TcR), a series of P1A35-43 peptides substituted by alanine at single positions was synthesized and tested for binding to H-2Ld and for CTL recognition. Binding to H-2Ld was estimated by measuring the ability of the peptide to up-regulate cell surface expression of H-2Ld. We found that three residues were important for interaction of P1A 35-43 with H-2Ld. Two of them, Pro at position 2 and Phe at position 9 were consistent with the described H-2Ld binding motif. A third residue, Trp at position 6, was also required for effective MHC binding of the tumor antigen. CTL sensitization assays showed that alanine substitution at position 7 (Leu) or at position 8 (Val) dramatically affected peptide recognition by anti-A CTL while positions 3 (Tyr) and 4 (Leu) were critical for recognition by anti-B CTL. We conclude that Pro2, Trp6 and Phe9 constitute the anchor residues of P1A 35-43 to H-2Ld, whereas the dipeptidyl sequences Tyr3-Leu4 and Leu7-Val8 form the core epitopes recognized by the TcR of anti-P815B and anti-P815A CTL, respectively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525302     DOI: 10.1002/eji.1830241125

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Emergence of virus escape mutants after immunization with epitope vaccine.

Authors:  G Weidt; W Deppert; O Utermöhlen; J Heukeshoven; F Lehmann-Grube
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

2.  Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity.

Authors:  Anil Shanker; Michel Buferne; Anne-Marie Schmitt-Verhulst
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

3.  Transgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis.

Authors:  Chi-Shan Li; Chong Chen; Pan Zheng; Yang Liu
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

4.  Specificity of the H-2 L(d)-restricted cytotoxic T-lymphocyte response to the mouse hepatitis virus nucleocapsid protein.

Authors:  C C Bergmann; S A Stohlman
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.

Authors:  J P Levraud; C Pannetier; P Langlade-Demoyen; V Brichard; P Kourilsky
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

6.  Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.

Authors:  M B Bloom; D Perry-Lalley; P F Robbins; Y Li; M el-Gamil; S A Rosenberg; J C Yang
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

7.  Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations.

Authors:  T Schweighoffer
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 2.874

8.  A single nine-amino acid peptide induces virus-specific, CD8+ human cytotoxic T lymphocyte clones of heterogeneous serotype specificities.

Authors:  J Zivny; I Kurane; A M Leporati; M Ibe; M Takiguchi; L L Zeng; M A Brinton; F A Ennis
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.